Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up


All communities will be placed in read-only mode (you will be able to see and search for posts but not start or reply to discussions) as we conduct maintenance. We will make another announcement when posting is re-opened. Thank you for your continued support and patience, and if you have any further questions, please email

Yours in health,
WebMD Community Management

Trastuzumab for Recurrent ER Pos patients
montrelblundell posted:
Some recent studies indicate that ER pos, Her2 neg patients with recurrent breast cancer may want to have their breast cancer mets retested for Her2. Many circulating breast cancer cells are turning out to be Her2 positive, making such patients eligible for trastuzumab and other solid her2 targeting therapies. Articles that talk about this: "Her2 and Breast Cancer Stem Cells: More than meets the Eye" in Cancer Research. And "HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer" in the NEJM. And "More Breast Cancer Patients Should Take Herceptin, Studies Hint" in Drug Discovery and Development.
Was this Helpful?
2 of 2 found this helpful

Helpful Tips

Be the first to post a Tip!

Related Drug Reviews

  • Drug Name User Reviews

Report Problems With Your Medications to the FDA

FDAYou are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

For more information, visit the Duke Health Breast Cancer Center